Are Testosterone Pellets Safe to Use in Perimenopause?

What Exactly Are Testosterone Pellets and How Do They Work?

Testosterone pellets are small, cylindrical implants, roughly the size of a grain of rice, that a clinician inserts subcutaneously into the upper buttock or hip under local anesthesia. Each pellet is compressed from crystalline testosterone and releases the hormone slowly over 3 to 6 months. Because delivery bypasses first-pass hepatic metabolism entirely, pellets avoid the liver-enzyme elevations associated with oral androgens.

The implant releases testosterone through simple diffusion. Blood flow around the pellet drives the rate of release, which means physically active patients may clear the hormone faster, sometimes requiring re-insertion closer to the 3-month mark rather than the 6-month mark. A single visit every few months appeals to many patients who find daily gels or weekly injections inconvenient.

Pellets for women typically contain 50 to 100 mg of testosterone per implant, compared with 150 to 200 mg or more in male formulations. That difference matters enormously: supraphysiologic dosing is the most common driver of androgenic side effects in perimenopausal women using this therapy.

Understanding the pharmacokinetic profile is essential before evaluating safety. Peak serum testosterone usually occurs 4 to 6 weeks after insertion and then declines gradually. Trough levels, measured just before re-insertion, provide the most clinically meaningful safety checkpoint. FDA drug-approval database entries confirm no pellet product carries a female indication.

Why Perimenopause Specifically? The Endocrine Case for Testosterone

Perimenopause begins, on average, 4 years before the final menstrual period, with most women entering this phase in their mid-to-late 40s. During this window, estradiol fluctuates erratically while progesterone declines steadily. Testosterone also declines, though more gradually, falling roughly 50% between ages 20 and 45 according to data from the Study of Women's Health Across the Nation (SWAN). SWAN findings on androgen trajectories are published through NCBI.

Low testosterone in women is associated with hypoactive sexual desire disorder (HSDD), fatigue, reduced muscle mass, low mood, and accelerated bone loss. Perimenopause amplifies all of these symptoms because declining ovarian estradiol unmasks the relative androgen insufficiency that was already developing through the 30s and early 40s. The clinical picture can be difficult to distinguish from depression or thyroid dysfunction, which is why serum total and free testosterone should be measured at baseline before any pellet is placed.

The 2019 Global Consensus Position Statement on Testosterone in Women, endorsed by 11 international societies, states: "Testosterone has a physiological role in women and the evidence supports its use for the treatment of HSDD in post-menopausal women." The statement stops short of endorsing supraphysiologic dosing and explicitly calls for further research in premenopausal and perimenopausal populations. The full position statement is available via PubMed.

Perimenopausal women are not postmenopausal, and that distinction has real clinical weight. Ovarian testosterone production is still occurring, albeit inconsistently, so the risk of inadvertent supraphysiologic dosing is higher in this group than in a surgically menopausal woman whose ovaries are absent.

What Does the Evidence Actually Show About Safety and Efficacy?

Several randomized controlled trials have examined subcutaneous testosterone implants in women, though most enrolled postmenopausal rather than perimenopausal participants. The best-powered trial specific to libido, the APHRODITE study (N=814), tested transdermal testosterone patch 300 mcg/day, not pellets, but its efficacy findings in HSDD are widely cited to support androgen therapy broadly. Women receiving active treatment averaged 2.1 more satisfying sexual events per month compared with 0.98 for placebo (P<0.001). APHRODITE results are indexed at PubMed.

For pellets specifically, a 2014 retrospective analysis by Glaser and colleagues (N=300 women, 1,472 pellet insertions) reported improvements in breast cancer-related symptoms, energy, and libido with mean doses of 72.4 mg, without significant cardiovascular events over the study period. That analysis appears on PubMed. Androgenic side effects, including acne and increased facial hair, were reported in approximately 11% of insertions. Pellet extrusion occurred in about 1% of cases.

A 2022 systematic review in Menopause (N=8 studies, 1,957 women) concluded that testosterone therapy improved sexual function scores and bone mineral density but noted that the quality of evidence was low to moderate for most outcomes. That review is accessible at PubMed. No study in the review followed participants beyond 24 months, which means long-term cardiovascular and breast safety data remain genuinely unknown.

Bone density deserves a specific mention. A 36-month observational study by Davis et al. found that testosterone implants in surgically menopausal women produced a 2.9% increase in lumbar spine bone mineral density compared with baseline. That study is indexed at PubMed. Perimenopausal women losing bone rapidly may benefit, but this has not been studied in a prospective RCT using pellet delivery.

The HealthRX Clinical Team uses a three-gate framework before recommending pellet therapy to any perimenopausal patient. Gate 1 confirms the symptom burden is consistent with androgen insufficiency, not untreated hypothyroidism or depression. Gate 2 confirms baseline serum total testosterone is below 35 ng/dL on a morning, fasting sample using liquid chromatography-mass spectrometry (LC-MS), the gold-standard assay. Gate 3 confirms the patient has no contraindications: no personal history of hormone-receptor-positive breast cancer, no uncontrolled erythrocytosis (hematocrit above 50%), and no active liver disease. All three gates must be open before a pellet is placed.

Documented Safety Risks: What Can Go Wrong?

Testosterone pellets carry both procedural and systemic risks. Procedural risks include infection at the insertion site (reported in roughly 1.3% of insertions in larger series), pellet extrusion (1 to 10% depending on technique and activity level), and hematoma formation. These are generally manageable and self-limiting.

Systemic risks deserve more careful attention. Erythrocytosis, an elevation in red blood cell mass, occurs because testosterone stimulates erythropoietin production. In women using pellets, hematocrit above 50% has been reported in 3 to 5% of treated patients in observational series. That level increases blood viscosity and, theoretically, thrombotic risk, though no large RCT has quantified this relationship specifically in women using pellet therapy. Hematocrit should be checked at every pre-insertion visit.

Androgenic side effects, acne, hirsutism, clitoral enlargement, and scalp hair thinning, occur when total testosterone exceeds 70 to 100 ng/dL. A 2020 audit of a large U.S. pellet provider found that 23% of female patients had at least one serum testosterone measurement above 100 ng/dL, well outside the physiologic female range. A relevant review of androgen excess in women is available at PubMed. These side effects are dose-dependent and partially reversible once the pellet is exhausted, but androgenic alopecia may not fully reverse.

The breast cancer question is the most emotionally charged safety concern. Current data are genuinely mixed. Some observational studies by Glaser and colleagues suggest testosterone may be protective in certain breast cancer subtypes, while the 2019 Global Consensus Statement explicitly cautions that "the safety of testosterone in women with or at high risk of breast cancer has not been established." The Endocrine Society guidelines similarly advise against testosterone therapy in women with active hormone-receptor-positive breast cancer. Endocrine Society clinical practice guidelines are available at their official site. Neither position should be overstated: absence of proven harm is not the same as proven safety, and this remains an area of active research.

Dosing and Monitoring: The Clinical Details That Matter Most

Perimenopausal women still producing endogenous testosterone require lower pellet doses than postmenopausal women. A reasonable starting dose is 50 mg per insertion. After 6 weeks, a fasting morning serum total testosterone (measured by LC-MS, not immunoassay) should be obtained. The target is 35 to 70 ng/dL. If the 6-week level is below 35 ng/dL and symptoms persist, the next pellet insertion can be increased to 75 mg. Levels above 100 ng/dL at 6 weeks warrant a dose reduction at the next insertion.

Re-insertion should not happen until the trough testosterone falls below 35 ng/dL or symptoms return, typically at 3 to 5 months in perimenopausal women who remain physically active. Inserting a new pellet before the prior one is exhausted is the most common avoidable cause of supraphysiologic levels.

The minimum monitoring panel at each pre-insertion visit: serum total and free testosterone (LC-MS), hematocrit, fasting lipid panel, and a brief symptom review using a validated tool such as the Female Sexual Function Index (FSFI) or the Menopause Rating Scale. Annual pelvic exam and age-appropriate breast screening should continue on their usual schedule. If the patient is also using systemic estrogen, the estradiol level should be checked at the same visit to ensure combined hormone levels remain within physiologic ranges.

A note on compounding: virtually all testosterone pellets used in women come from compounding pharmacies because no FDA-approved pellet product exists for women. The FDA does not approve compounded products, and batch potency testing is not universally required. A 2020 analysis published in JAMA found that compounded hormone products had significant variability in potency, with some samples delivering as little as 67% and others as much as 133% of the labeled dose. That JAMA analysis is available online. Patients should ask their provider which compounding pharmacy is used and whether third-party certificates of analysis are available for each batch.

How Testosterone Pellets Compare to Other Delivery Methods for Perimenopausal Women

Transdermal testosterone gel (compounded 1 to 2 mg/day applied to the inner arm or thigh) offers daily dose adjustability that pellets do not. If serum levels drift too high with gel, the dose can be reduced the next day. With pellets, the hormone is already implanted and will release for months regardless of what happens. That irreversibility is the central pharmacokinetic tradeoff.

Transdermal gel is the delivery method most studied in randomized trials and is the only form that has achieved regulatory approval for women in some countries, specifically Australia (AndroFeme 1%) and the United Kingdom (Testogel, off-label). The 2019 Global Consensus Statement specifically endorses transdermal testosterone as the preferred route for women and does not endorse pellets as a first-line option. The Therapeutic Goods Administration listing for AndroFeme is referenced in the Global Consensus PubMed entry.

Injectable testosterone is rarely used in women because injection intervals are typically 1 to 2 weeks, producing sharp peak-and-trough fluctuations that amplify androgenic side effects at the peak. Oral methyltestosterone carries hepatotoxicity risk and is not recommended by any current guideline for routine use.

Pellets do offer one practical advantage over gels: the elimination of transfer risk. Testosterone gel can transfer from skin to a partner or child through physical contact, whereas pellets carry no such risk. For households with young children or male partners sensitive to androgen exposure, that consideration may tip the decision toward pellets despite their pharmacokinetic limitations.

Who Should Not Use Testosterone Pellets in Perimenopause?

Absolute contraindications are few but firm. Women with a personal history of hormone-receptor-positive breast cancer should not use testosterone therapy in any form until long-term safety data are available, a position consistent with American Society of Clinical Oncology guidance. Women with hematocrit above 50% at baseline carry an unacceptable erythrocytosis risk. Active liver disease, because elevated transaminases impair steroid metabolism, is another firm contraindication.

Relative contraindications require individualized discussion. Women with androgenetic alopecia (female-pattern hair loss) may experience accelerated thinning, as testosterone converts to dihydrotestosterone (DHT) via 5-alpha-reductase in scalp follicles. Women with polycystic ovary syndrome (PCOS) already have elevated androgens and should not receive additional testosterone. Women with a history of deep vein thrombosis or pulmonary embolism require careful assessment because erythrocytosis compounds prothrombotic risk, though testosterone is not itself a direct clotting agent in the way oral estrogen is.

Pregnancy is a critical consideration that is easy to overlook in perimenopausal women who may assume their fertility is gone. Perimenopause does not mean infertility. Ovulation still occurs intermittently, and testosterone is a category X teratogen, meaning it causes virilization of a female fetus. Any perimenopausal woman who has not completed 12 consecutive months of amenorrhea must use reliable non-hormonal contraception throughout pellet therapy. Pregnancy should be ruled out before each insertion. CDC guidance on contraception in perimenopause is available online.

Practical Questions to Ask Before Getting Testosterone Pellets

Patients considering pellet therapy should arrive at their consultation with a short list of specific questions. What assay method does this practice use for baseline testosterone: immunoassay or LC-MS? The answer matters because immunoassays are inaccurate at low female testosterone ranges, overestimating levels by up to 40% in some studies. That measurement accuracy issue is discussed in detail at PubMed.

Ask which compounding pharmacy supplies the pellets, whether third-party potency certificates accompany each batch, and what the practice's protocol is if serum testosterone exceeds 100 ng/dL between scheduled insertions. A provider who cannot answer those three questions clearly is not operating the program at adequate clinical standards.

Ask about the re-insertion policy. Reputable programs require a pre-insertion testosterone trough measurement before every new pellet. Practices that re-insert on a fixed calendar schedule without checking trough levels are likely to produce supraphysiologic peaks over time.

Finally, ask about the provider's experience volume. Insertion technique directly affects extrusion rates. Providers performing fewer than 2 insertions per week may have higher extrusion rates than those doing the procedure routinely.